Transmedics Group (TMDX) Stock Price

Transmedics Group Price

NASDAQ·CLOSED
76.51USD+0.38 (+0.50 %)
Market closed

Revenue has compounded at 66.3% per year over the past 9 years to 605.49 M USD. Transmedics Group's net margin stands at 31.4%, up from -146.1% several years earlier. Analysts set a median price target of 151.98 USD, implying 98.6% above the current price. Of 20 analysts, 16 rate the stock a buy — an overall Buy consensus. The stock trades about 23% above its 52-week low.

Transmedics Group stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Transmedics Group over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Transmedics Group stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Transmedics Group's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Transmedics Group Stock Price History
DateTransmedics Group Price
7/31/202676.51 USD
7/30/202676.13 USD
7/29/202675.83 USD
7/27/202673.06 USD
7/23/202671.13 USD
7/22/202671.20 USD
7/21/202674.29 USD
7/20/202673.47 USD
7/17/202673.98 USD
7/16/202676.00 USD
7/15/202675.38 USD
7/14/202674.59 USD
7/13/202676.51 USD
7/10/202671.23 USD
7/9/202672.19 USD
7/8/202670.31 USD
7/7/202671.11 USD
7/6/202672.53 USD
7/2/202668.86 USD
7/1/202667.85 USD
6/30/202666.42 USD
6/29/202667.68 USD
6/26/202668.44 USD
6/25/202677.75 USD
6/24/202677.61 USD
6/23/202673.83 USD
6/22/202676.36 USD
6/18/202679.77 USD
6/17/202677.19 USD
6/16/202675.79 USD
6/15/202676.10 USD
6/12/202673.81 USD
6/11/202674.16 USD
6/10/202675.60 USD
6/9/202674.29 USD
6/8/202671.14 USD
6/5/202671.60 USD
6/4/202672.30 USD
6/3/202667.91 USD
6/2/202669.19 USD
6/1/202668.06 USD
5/29/202667.39 USD
5/28/202668.21 USD
5/27/202668.93 USD
5/26/202669.60 USD
5/22/202668.10 USD
5/21/202667.19 USD
5/20/202669.18 USD
5/19/202666.13 USD
5/18/202668.34 USD
5/15/202663.20 USD
5/14/202662.04 USD
5/13/202664.18 USD
5/12/202663.93 USD
5/11/202664.30 USD
5/8/202667.84 USD
5/7/202672.90 USD
5/6/202672.92 USD
5/5/202694.93 USD
5/4/202697.08 USD
5/1/2026100.01 USD
4/30/2026100.79 USD
4/29/202698.57 USD
4/28/2026101.26 USD
4/27/2026108.12 USD
4/24/2026110.93 USD
4/22/2026114.65 USD
4/21/2026108.91 USD
4/20/2026113.13 USD
4/17/2026115.87 USD
4/16/2026109.12 USD
4/15/2026116.11 USD
4/14/2026115.68 USD
4/13/2026113.36 USD
4/10/2026114.00 USD
4/9/2026109.20 USD
4/8/2026109.36 USD
4/7/2026107.32 USD
4/6/2026104.81 USD
4/2/2026100.70 USD
4/1/2026100.40 USD
3/31/202699.41 USD
3/30/202694.31 USD
3/27/202699.39 USD
3/26/2026102.20 USD
3/25/2026106.51 USD
3/24/2026110.20 USD
3/23/2026112.08 USD
3/20/2026115.72 USD
3/19/2026113.72 USD
3/18/2026113.72 USD
3/17/2026124.51 USD
3/16/2026125.51 USD
3/13/2026122.52 USD
3/12/2026121.31 USD
3/11/2026128.59 USD
3/10/2026130.85 USD
3/9/2026134.77 USD
3/6/2026130.51 USD
3/5/2026140.07 USD
3/4/2026147.66 USD
3/3/2026148.00 USD
3/2/2026147.00 USD
2/27/2026145.26 USD
2/26/2026134.57 USD
2/25/2026131.85 USD
2/24/2026137.78 USD
2/23/2026134.65 USD
2/20/2026134.25 USD
2/19/2026132.88 USD
2/18/2026135.50 USD
2/17/2026133.82 USD
2/13/2026129.84 USD
2/12/2026128.52 USD
2/11/2026133.30 USD
2/10/2026139.29 USD
2/9/2026136.34 USD
2/6/2026135.06 USD
2/5/2026128.76 USD
2/4/2026130.37 USD
2/3/2026135.72 USD
2/2/2026133.99 USD
1/30/2026133.51 USD
1/29/2026138.97 USD
1/28/2026144.83 USD
1/27/2026138.49 USD
1/26/2026139.01 USD
1/23/2026135.01 USD
1/22/2026138.09 USD
1/21/2026135.70 USD
1/20/2026141.93 USD
1/16/2026143.37 USD
1/15/2026143.69 USD
1/14/2026141.96 USD
1/13/2026142.71 USD
1/12/2026134.66 USD
1/9/2026137.07 USD
1/8/2026138.01 USD
1/7/2026137.27 USD
1/6/2026132.67 USD
1/5/2026126.28 USD
1/2/2026122.69 USD
12/31/2025121.65 USD
12/30/2025121.53 USD
12/29/2025123.06 USD
12/26/2025124.20 USD
12/24/2025126.99 USD
12/23/2025128.20 USD
12/22/2025129.35 USD
12/19/2025127.67 USD
12/18/2025121.07 USD
12/17/2025122.43 USD
12/16/2025125.85 USD
12/15/2025122.07 USD
12/12/2025127.01 USD
12/11/2025127.62 USD
12/10/2025131.21 USD
12/9/2025134.80 USD
12/8/2025139.56 USD
12/5/2025136.51 USD
12/4/2025138.63 USD
12/3/2025140.10 USD
12/2/2025142.88 USD
12/1/2025151.01 USD
11/28/2025146.31 USD
11/26/2025145.46 USD
11/25/2025147.03 USD
11/24/2025139.32 USD
11/21/2025130.93 USD
11/20/2025122.01 USD
11/19/2025133.00 USD
11/18/2025121.01 USD
11/17/2025113.40 USD
11/14/2025115.01 USD
11/13/2025115.55 USD
11/12/2025119.18 USD
11/11/2025122.14 USD
11/10/2025122.39 USD
11/7/2025119.17 USD
11/6/2025123.71 USD
11/5/2025124.46 USD
11/4/2025122.21 USD
11/3/2025123.71 USD
10/31/2025131.54 USD
10/30/2025135.06 USD
10/29/2025123.81 USD
10/28/2025130.51 USD
10/27/2025131.53 USD
10/24/2025130.11 USD
10/23/2025129.47 USD
10/22/2025119.54 USD
10/21/2025120.01 USD
10/20/2025119.90 USD
10/17/2025117.51 USD
10/16/2025115.68 USD
10/15/2025112.61 USD
10/14/2025111.23 USD
10/13/2025111.71 USD
10/10/2025106.51 USD
10/9/2025113.19 USD
10/8/2025118.06 USD
10/7/2025117.00 USD
10/6/2025114.03 USD
10/3/2025115.34 USD
10/2/2025116.07 USD
10/1/2025115.01 USD
9/30/2025112.20 USD
9/29/2025112.20 USD
9/28/2025112.64 USD
9/25/2025113.87 USD
9/24/2025113.90 USD
9/23/2025120.55 USD
9/22/2025126.62 USD
9/19/2025123.00 USD
9/18/2025121.70 USD
9/17/2025119.81 USD
9/16/2025119.15 USD
9/15/2025114.29 USD
9/12/2025114.86 USD
9/11/2025116.99 USD
9/10/2025107.70 USD
9/9/2025109.01 USD
9/8/2025106.86 USD
9/5/2025104.51 USD
9/4/2025104.05 USD
9/3/2025107.19 USD
9/2/2025112.00 USD
8/29/2025115.02 USD
8/28/2025116.73 USD
8/27/2025117.38 USD
8/26/2025115.19 USD
8/25/2025115.51 USD
8/22/2025119.51 USD
8/21/2025118.76 USD
8/20/2025121.88 USD
8/19/2025122.33 USD
8/18/2025125.48 USD
8/15/2025127.01 USD
8/14/2025129.74 USD
8/13/2025132.04 USD
8/12/2025131.13 USD
8/11/2025127.26 USD
8/8/2025122.01 USD
8/7/2025116.05 USD
8/6/2025118.51 USD
8/5/2025125.74 USD
8/4/2025129.35 USD
Access this data via the Eulerpool API
Get Free API Key

Transmedics Group Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
93.46 M USD
-32.44 M USD
-36.23 M USD
Jan 1, 2023
241.62 M USD
-28.73 M USD
-25.03 M USD
Jan 1, 2024
441.54 M USD
37.50 M USD
35.46 M USD
Jan 1, 2025
605.49 M USD
108.58 M USD
190.29 M USD
Jan 1, 2026 (e)
732.29 M USD
-160.93 M USD
60.98 M USD
Jan 1, 2027 (e)
867.85 M USD
-190.72 M USD
105.31 M USD
Jan 1, 2028 (e)
1.01 B USD
-221.45 M USD
154.96 M USD
Jan 1, 2029 (e)
1.17 B USD
-258.09 M USD
186.23 M USD

Transmedics Group Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 4, 2026, 1:57 PM
 
REVENUEB USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
200620162017201820192020202120222023202420252026e2027e2028e2029e
–0.010.010.010.020.030.030.090.240.440.610.730.871.011.17
––16.6785.7176.928.7020.00210.00159.1482.9937.1920.9918.4416.1516.58
–6,033.3328.5738.4656.5264.0070.0069.8963.9059.4159.8359.8359.8359.8359.83
362.00362.002.005.0013.0016.0021.0065.00154.00262.00362.00437.99518.77602.54702.46
-18.00-23.00-19.00-20.00-29.00-24.00-40.00-32.00-28.0037.00108.00-160.00-190.00-221.00-258.00
–-383.33-271.43-153.85-126.09-96.00-133.33-34.41-11.628.3917.85-21.86-21.91-21.95-21.98
-17.00-24.00-20.00-23.00-33.00-28.00-44.00-36.00-25.0035.00190.0060.00105.00154.00186.00
–41.18-16.6715.0043.48-15.1557.14-18.18-30.56-240.00442.86-68.4275.0046.6720.78
40.9340.934.6519.2521.1727.1627.7732.0134.1835.2140.9340.9340.9340.9340.93
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Transmedics Group generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Transmedics Group retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Transmedics Group's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Transmedics Group has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Transmedics Group's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Transmedics Group stock margins

The Transmedics Group margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Transmedics Group. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Transmedics Group.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
69.92 %
-133.19 %
-146.11 %
Jan 1, 2022
69.84 %
-34.71 %
-38.77 %
Jan 1, 2023
63.77 %
-11.89 %
-10.36 %
Jan 1, 2024
59.36 %
8.49 %
8.03 %
Jan 1, 2025
59.92 %
17.93 %
31.43 %
Jan 1, 2026 (e)
59.92 %
-21.98 %
8.33 %
Jan 1, 2027 (e)
59.92 %
-21.98 %
12.13 %
Jan 1, 2028 (e)
59.92 %
-21.98 %
15.38 %

Transmedics Group Stock Revenue, EBIT, Earnings per Share

The Transmedics Group earnings per share therefore indicates how much revenue Transmedics Group has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
1.09 USD
-1.45 USD
-1.59 USD
Jan 1, 2022
2.92 USD
-1.01 USD
-1.13 USD
Jan 1, 2023
7.07 USD
-0.84 USD
-0.73 USD
Jan 1, 2024
12.54 USD
1.06 USD
1.01 USD
Jan 1, 2025
14.79 USD
2.65 USD
4.65 USD
Jan 1, 2026 (e)
21.43 USD
-3.93 USD
1.78 USD
Jan 1, 2027 (e)
25.40 USD
-4.66 USD
3.08 USD
Jan 1, 2028 (e)
29.49 USD
-5.41 USD
4.54 USD

Transmedics Group business model & stock analysis

Transmedics Group Inc is a company dedicated to the development and manufacturing of medical devices for organ transplantation. The company was founded in 1998 and is headquartered in Andover, Massachusetts, USA. Transmedics' business model is based on offering a unique and innovative technology for organ preservation during transport from donor to recipient. The patented Organ Care System (OCS) platform includes a range of state-of-the-art medical devices specifically designed for organ transport. Transmedics' Organ Care System includes three main devices: OCS Heart, OCS Lung, and OCS Liver. Each device is tailored for organ preparation and transport, providing individualized support based on the specific requirements of each organ and different transfer protocols. The OCS technology uses hypothermic (cold) perfusion to preserve the organ during transport. By continuously monitoring and supporting the organ's physiological functions, the OCS system can improve the survival rate of donor organs while reducing the time spent outside the body. Transmedics also offers comprehensive services, including the availability of OCS devices and qualified personnel to provide support throughout the transplantation process. Transmedics' customers include leading transplant centers and hospitals worldwide. The company works closely with these customers to ensure that its OCS devices meet the specific requirements of each transplantation program and help them achieve more successful transplantations. Transmedics' history is marked by a passion for improving transplantation medicine and saving lives through the provision of advanced technologies and solutions. The company has made significant progress in recent years and has experienced strong growth in all areas. Transmedics has also received a number of awards and recognition for its commitment to improving transplantation medicine. For example, in 2020, the company received the Red Herring Top 100 Global Award and was recognized for the seventh consecutive year as one of the fastest-growing companies by Deloitte. Overall, Transmedics is a leading provider of innovative medical devices for transplantation medicine. Through its organic technology and comprehensive service, the company supports transplant centers and hospitals worldwide in performing more successful transplantations and saving patients' lives.

Transmedics Group SWOT Analysis

Strengths

Transmedics Group Inc has several key strengths that contribute to its competitive position in the market:

  • Advanced Organ Care System (OCS) technology, providing a superior solution for the preservation and transport of donor organs.
  • Strong intellectual property portfolio, including patents related to OCS technology and organ preservation methods.
  • Established partnerships with leading transplant centers and healthcare institutions globally, offering a wide customer base.
  • Experienced management team with deep industry knowledge and a track record of successful execution.
  • Continued focus on research and development to enhance existing products and develop new technologies.

Weaknesses

Despite its strengths, Transmedics Group Inc also faces certain weaknesses that could impact its performance:

  • Highly specialized products, limiting the company's target market to healthcare providers involved in organ transplantation.
  • Reliance on regulatory approvals and reimbursement policies, which can create delays and uncertainty in market access.
  • Potential vulnerability to competitors entering the organ preservation and transportation market.

Opportunities

Transmedics Group Inc can explore various opportunities to further grow its business and market presence:

  • Expansion into emerging markets where organ transplantation rates are increasing.
  • Collaboration with pharmaceutical companies to develop complementary therapies or drugs for improved organ transplant outcomes.
  • Increased adoption of OCS technology as the standard for organ preservation and transportation.
  • Strategic acquisitions or partnerships to enhance product offerings or expand into adjacent market segments.

Threats

Transmedics Group Inc should also consider potential threats that could impact its future success:

  • Stringent regulatory requirements governing the approval and use of medical devices, including OCS technology.
  • Fluctuations in healthcare spending and reimbursement policies, which could affect customer demand and pricing.
  • Intense competition from existing competitors and potential new entrants in the organ preservation and transportation market.
  • Rapid advancements in alternative technologies or treatment methods that could disrupt the organ transplantation industry.

Transmedics Group Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Transmedics Group Employees
Details
Date
Transmedics Group Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Transmedics Group Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Transmedics Group historical P/E ratio, EBIT multiple, and P/S ratio

Transmedics Group annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Transmedics Group shares outstanding

The number of shares of Transmedics Group was 40.93 M in 2025. This indicates how many shares Transmedics Group is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
27.77 M Stocks
Jan 1, 2022
32.01 M Stocks
Jan 1, 2023
34.18 M Stocks
Jan 1, 2024
35.21 M Stocks
Jan 1, 2025
40.93 M Stocks
Jan 1, 2026 (e)
40.93 M Stocks
Jan 1, 2027 (e)
40.93 M Stocks
Jan 1, 2028 (e)
40.93 M Stocks

Current Transmedics Group forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.34 %
Buy
80.00 % (16)
Hold
20.00 % (4)
Sell
0.00 % (0)
12M Price Target
151.98
Last Price
76.51
Currency
USD
12M Return Potential
98.64 %
LTM Return
0 %

Transmedics Group Analyst Rating Actions

DateFirmActionRatingReliability
7/6/2026
Evercore ISI Group
Evercore ISI Group
MaintainedOutperform62
7/1/2026
TD Cowen
TD Cowen
MaintainedBuy60
6/30/2026
Canaccord Genuity
Canaccord Genuity
MaintainedBuy59
6/18/2026
Stifel
Stifel
MaintainedHold–
5/26/2026
Stifel
Stifel
MaintainedHold–
5/6/2026
TD Cowen
TD Cowen
MaintainedBuy60
5/6/2026
Stifel
Stifel
MaintainedHold–
5/6/2026
Piper Sandler
Piper Sandler
MaintainedOverweight51
5/6/2026
Needham
Needham
MaintainedBuy70
5/6/2026
Canaccord Genuity
Canaccord Genuity
MaintainedBuy59

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Transmedics Group Earnings Calls

2025

Transmedics Group Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
7/30/20260.49USD-187.03 MUSD-2026 Q2
5/6/20260.63USD-175.60 MUSD-2026 Q1
3/4/20260.40USD-158.83 MUSD-2025 Q4
4/29/2024-0.23USD-76.15 MUSD-2024 Q1
2/20/2024-0.03USD-70.49 MUSD-2023 Q4
7/31/2023-0.29USD-33.41 MUSD-2023 Q2
5/1/2023-0.28USD-28.80 MUSD-2023 Q1
2/21/2023-0.30USD-24.82 MUSD-2022 Q4
11/3/2022-0.42USD-19.16 MUSD-2022 Q3
8/1/2022-0.36USD-16.52 MUSD-2022 Q2

EESG©

Eulerpool ESG Scorecard© for the Transmedics Group stock

48/100
45
Environment
34
Social
65
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees48.4
Percentage of women in management—
Percentage of Asian employees10.4
Share of Asian management14.5
Percentage of Hispanic/Latino employees7.5
Hispano/Latino Management share6
Percentage of Black employees1.1
Black Management Share—
Percentage of white employees80.6
White Management Share79.5
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Transmedics Group shareholder structure

% Name
15.49116%
BLACKROCK, INC.
BLACKROCK, INC.
14.91438%
FMR LLC
FMR LLC
5.61760%
VANGUARD PORTFOLIO MANAGEMENT LLC
VANGUARD PORTFOLIO MANAGEMENT LLC
4.32588%
VANGUARD CAPITAL MANAGEMENT LLC
VANGUARD CAPITAL MANAGEMENT LLC
3.86151%
STATE STREET CORP
STATE STREET CORP
3.03768%
INVESCO LTD.
INVESCO LTD.
...

Transmedics Group Beneficial Ownership Filings (SEC 13D/G)

Free Float
96.7%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
15.00%
FMR LLC
FMR LLC
SEC ↗
14.60%
BlackRock, Inc.
BlackRock, Inc.
SEC ↗
6.89%
United Therapeutics Corporation
United Therapeutics Corporation
SEC ↗
6.89%
Lung Biotechnology PBC
Lung Biotechnology PBC
SEC ↗
6.80%
(1) BlackRock, Inc.
(1) BlackRock, Inc.
SEC ↗
6.60%
Abigail P. Johnson
Abigail P. Johnson
SEC ↗
6.50%
Sandhill Capital Partners LLC d/b/a Sandhill Investment Management
Sandhill Capital Partners LLC d/b/a Sandhill Investment Management
SEC ↗
5.95%
Macquarie Management Holdings Inc
Macquarie Management Holdings Inc
SEC ↗
5.95%
Macquarie Investment Management Business Trust
Macquarie Investment Management Business Trust
SEC ↗
5.95%
Macquarie Group Limited
Macquarie Group Limited
SEC ↗

Transmedics Group Executives and Management Board

12 members · avg. age 62 · 17 % women

WH

Dr. Waleed Hassanein (56)

President, Chief Executive Officer, Director · since 1998

8.20 M USD

Management

TK

Dr. Tamer Khayal (56)

Chief Commercial Officer

3.08 M USD
NC

Mr. Nicholas Corcoran (43)

Senior Vice President - Supply Chain and Operations

2.72 M USD
GH

Mr. Gerardo Hernandez (54)

Chief Financial Officer, Treasurer

1.76 M USD
AR

Mr. Anil Ranganath (44)

Senior Vice President, General Counsel, Corporate Secretary

594,250.00 USD

Board of Directors

JT

Mr. James Tobin (80)

Independent Chairman of the Board

300,857.00 USD
MR

Ms. Merilee Raines (69)

Independent Director

279,309.00 USD
TG

Mr. Thomas Gunderson (74)

Independent Director

278,865.00 USD
EB

Mr. Edward Basile (77)

Independent Director

272,081.00 USD
SL

Ms. Stephanie Lovell (65)

Independent Director

263,357.00 USD
DW

Dr. David Weill (61)

Independent Director

263,357.00 USD

Frequently asked questions about Transmedics Group

Transmedics Group Inc. operates under a business model focused on the development and commercialization of organ transplant solutions. The company specializes in designing and producing innovative medical devices and systems that preserve, monitor, and assess organs intended for transplantation. By harnessing cutting-edge technology, Transmedics' business model aims to improve both donor organ quality and transplantation outcomes. Through its offerings, the company seeks to address critical challenges faced by organ transplant patients and healthcare professionals worldwide. Transmedics Group Inc. continues to drive innovation in the organ transplant field through its comprehensive product portfolio and commitment to advancing patient care.

Transmedics Group Inc is primarily active in the biomedical industry.

The main competitors of Transmedics Group Inc in the market include Medtronic, Inc., XVIVO Perfusion AB, and OrganAssist BV.

Transmedics Group Inc is a leading medical technology company specializing in organ transplant solutions. Founded in 1998, the company has been dedicated to improving outcomes for patients awaiting organ transplants. With its groundbreaking Organ Care System (OCS), Transmedics revolutionized the field by allowing organs to be preserved and assessed outside the traditional cold storage method. This breakthrough technology ensures organs remain at the optimal physiological condition, significantly increasing the chances of successful transplants. Transmedics is committed to continuing innovation and expanding its global presence to address the critical need for organ transplantation worldwide.

Transmedics Group Inc has achieved several significant milestones. Notably, the company successfully developed the Organ Care System (OCS), a breakthrough technology that allows for the preservation and transportation of donor organs. The OCS has revolutionized the field of transplant medicine by extending the time organs can remain outside the body, increasing the chances of successful transplantation. Additionally, Transmedics Group Inc received regulatory approvals for the OCS in major markets, including the United States and Europe. These achievements have solidified the company's position as a leader in the advancement of organ transplantation, benefiting countless patients worldwide.

Transmedics Group Inc is primarily present in the United States.

Transmedics Group Inc represents a commitment to innovation and improving organ transplant outcomes. The company's corporate philosophy centers around its Organ Care System (OCS) technology, which enables the preservation and assessment of donated organs for transplantation. Transmedics Group Inc values the advancements made in organ transplantation, aiming to improve patient outcomes and increase the number of viable organs available for transplant. By leveraging their OCS technology, the company strives to address the critical organ shortage challenge and revolutionize the transplantation field. Through their dedication to innovation and patient-centric approach, Transmedics Group Inc constantly aims to make a positive impact in the field of organ transplantation.

Analysts currently set an average price target of 148.92 USD for the Transmedics Group stock (median: 151.98 USD), implying +94.6 % versus the latest price. The consensus is based on 20 analyst ratings.

Transmedics Group Analyst Price Targets 2026

20 analysts currently rate the Transmedics Group stock: 16 recommend buying, 4 holding and 0 selling. For 2026, analysts expect Transmedics Group to generate revenue of 732.29 M USD and earnings per share of 1.49 USD.

Transmedics Group Analyst Price Targets 2026

Converted at the current exchange rate, the Transmedics Group share trades at 66.47 EUR (76.51 USD).

The Transmedics Group share (TMDX) is listed on 3 stock exchanges, including: NASDAQ (TMDX), Frankfurt (8T8.F), München (8T8.MU).

The Transmedics Group Inc is a leading provider of advanced organ care systems for transplantation medicine. The company offers an innovative platform that allows organs to be obtained, protected, transported, and transplanted outside of the body. The company is divided into three main business areas: 1. Organ Care System The Organ Care System (OCS) is a groundbreaking technology that revolutionizes organ care and transplantation. It is a portable, modular system that enables doctors to obtain and protect donor organs outside of the body. The OCS was developed to increase the survival rate of donor organs and reduce the number of transplant rejections. 2. Organ Transport & Storage Solutions The company offers a variety of organ transport and storage solutions that meet the needs of customers. The transport and storage systems are FDA-certified and provide optimal conditions for successful transplantation. 3. Organ Care Services Organ Care Services (OCS) are a key part of Transmedics' business operations. The company offers a wide range of services tailored to the specific needs of customers. These include organ storage, preparation for transplantation, and support during surgeries. Transmedics is an innovative company protected by a number of patents and intellectual property. The company heavily invests in research and development and stays at the forefront of technology to maintain its position as a leader in organ transplantation. In summary, Transmedics Group Inc is a pioneer in the field of organ transplantation. With its offering of advanced organ care systems, the company has revolutionized transplantation medicine and established itself as a leading provider. Transmedics is well-positioned to continue growing and meeting the needs of its customers while helping to save lives.

The expected revenue of Transmedics Group is 732.29 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Transmedics Group is 60.98 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Transmedics Group is currently 51.35. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Transmedics Group stock.

The price-to-sales ratio (P/S) of Transmedics Group is currently 4.28. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Transmedics Group stock.

The Eulerpool Quality Score for Transmedics Group is 6/10.

The ISIN of Transmedics Group is US89377M1099. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Transmedics Group is A2PH5P. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Transmedics Group is TMDX. The ticker symbol is used to trade Transmedics Group shares on the stock exchange.

Transmedics Group paid dividends every year for the past 0 years.

Transmedics Group is assigned to the 'Health' sector.

The dividends of Transmedics Group are distributed in USD.

All fundamentals and in-depth analysis of Transmedics Group

Our stock analysis for Transmedics Group stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Transmedics Group. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Transmedics Group Stock
Transmedics Group Revenue→
Transmedics Group Stock
Transmedics Group Net Income→
Transmedics Group Stock
Transmedics Group P/E→
Transmedics Group Stock
Transmedics Group P/S→
Transmedics Group Stock
Transmedics Group EBIT→
Transmedics Group Stock
Transmedics Group Dividend→
Transmedics Group Stock
Transmedics Group Directors Dealings→
Transmedics Group Stock
Transmedics Group Stocks→
Transmedics Group Stock
Transmedics Group Market capitalization→
Transmedics Group Stock
Transmedics Group Debt→
Transmedics Group Stock
Transmedics Group Liabilities→
Transmedics Group Stock
Transmedics Group Equity→
Transmedics Group Stock
Transmedics Group AAQS→
Transmedics Group Stock
Transmedics Group Employees→
Transmedics Group Stock
Transmedics Group ROE→
Transmedics Group Stock
Transmedics Group ROA→
Transmedics Group Stock
Transmedics Group ROCE→
Transmedics Group Stock
Transmedics Group News→
Transmedics Group Stock
Transmedics Group Analyst Price Targets→

Health Stocks

TransThera Sciences (Nanjing)TransGenic GroupTraphaco JSCTransgene BiotekTravere TherapeuticsTransgeneTraws PharmaTranscode TherapeuticsTreace Medical ConceptsTranschemTrevenaTranscenta HoldingAll Stocks A–Z →